Tech Session II: Nanomedicine and Nanoscale Delivery (Focus: Nervous)
NLC for Intranasal Delivery in Alzheimer’s disease-Pharmacokinetic, Biodistribution and PD study
Tuesday, July 15, 2025
3:05 PM – 3:16 PM EDT
Introduction: Alzheimer's disease (AD) is complex neurodegenerative disorder that remains challenging to treat with monotherapy. This complexity underscores the need for combination therapies, which offer a more effective treatment strategy. In this study, a dual approach was explored by combining an acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzyme inhibitor (RV) with a kinase inhibitor (KI) for managing AD. This innovative combination targets multiple pathways involved in AD progression, potentially improving therapeutic outcomes and addressing the limitations of single-drug treatments.
Learning Objectives:
At the completion of this activity, participants will know
Understand the Role of Combination Therapy in AD management
Interpret results (PK, PD and BD) between NLCs and suspension when administered via intranasal route
Comparitive Evaluation of NOR and EPM tests to assess cognitive and behavioral improvements in AD.
